IDECABTAGENE VICLEUCEL
UNII 8PX1X7UG4D

Substance Identification & Data

This profile provides standardized clinical and technical data for Idecabtagene Vicleucel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 8PX1X7UG4D.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) 2536430. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

8PX1X7UG4D

CAS Registry Number

N/A

RxNorm Concept ID

2536430

Detailed Substance Profile

Preferred Name

IDECABTAGENE VICLEUCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

Molecular Formula

8PX1X7UG4D

The specific atomic composition represented as a molecular structure string.

NCI Thesaurus

C117729

National Cancer Institute reference terminology for clinical and research data.

INN ID

10906

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

GH-44

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Idecabtagene Vicleucel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

IDECABTAGENE VICLEUCEL

Common Names & Synonyms

ANTI-BCMA CAR T CELL

HUMAN CULTURE EXPANDED GENETICALLY MODIFIED AUTOLOGOUS T CELLS FOR CELL-BASED GENE THERAPY. CELLS ARE DERIVED FROM ISOLATED BLOOD OF THE PATIENT AND ARE TRANSDUCED WITH NON-REPLICATIVE SELF-INACTIVATING (SIN) HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) BASED LENTIVIRAL VECTOR (LVV) PSEUDOTYPED WITH THE VESICULAR STOMATITIS VIRUS GLYCOPROTEIN G (VSV-G) ENVELOPE PROTEIN, AND ENCODING THE C11D5.3 ANTI-TNF RECEPTOR SUPERFAMILY MEMBER 17 (TNFRSF17, BCMA) SINGLE CHAIN VARIABLE FRAGMENT (SCFV) CD8/4-1BB/CD3ZETA CHIMERIC ANTIGEN RECEPTOR (CAR) UNDER THE TRANSCRIPTIONAL CONTROL OF THE MYELOPROLIFERATIVE SARCOMA VIRUS ENHANCER, NEGATIVE CONTROL REGION DELETED, DL587REV PRIMER-BINDING SITE SUBSTITUTED (MND) PROMOTE

IDECABTAGENE VICLEUCEL [INN]

IDECABTAGENE VICLEUCEL [USAN]

IDECABTAGENE VICLEUCEL [WHO-DD]

IDE-CEL